Key facts
- This page summarizes David Hallal's Form 4 filing for iTeos Therapeutics, Inc. (ITOS).
- 9 reported transactions and 3 derivative rows are listed below.
- Accepted by SEC: 06 Jun 2025, 21:03.
David Hallal - 04 Jun 2025 Form 4 Insider Report for iTeos Therapeutics, Inc. (ITOS)
- Reporting relationship
- Director
- Issuer ticker
- ITOS
- Reported as of
- 04 Jun 2025
- Net transaction value
- -$671,272
- SEC form
- 4
- Accepted by SEC
- 06 Jun 2025, 21:03:02 UTC
- Prior SEC filing
- 06 May 2025
- Next SEC filing
- 29 Aug 2025
- Source filing
- View source filing
- Reporting owner signature
- /s/ Adi Osovsky, as Attorney-in-Fact
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
David Hallal filed Form 4 for iTeos Therapeutics, Inc. (ITOS) on 06 Jun 2025.
Change
- Previous filing in this sequence was filed on 06 May 2025.
- Current net transaction value: -$671,272.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reporting Owners (1)
CIK 0001457477
Primary reporting owner
Hallal David
- Relationship
- Director
- Address
- C/O ITEOS THERAPEUTICS, INC., 321 ARSENAL STREET, WATERTOWN
- Signature
- /s/ Adi Osovsky, as Attorney-in-Fact
- Signature date
- 06 Jun 2025
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
ITOS
transaction
Common Stock
Options Exercise
- Transaction value
- $164,376
- Shares
- +38,227
- Change %
- Price
- $4.30
- Shares after
- 38,227
- Date
- 04 Jun 2025
- Ownership
- Direct
- Footnotes
- F1
ITOS
transaction
Common Stock
Sale
- Transaction value
- $384,946
- Shares
- -38,227
- Change %
- -100%
- Price
- $10.07
- Shares after
- 0
- Date
- 04 Jun 2025
- Ownership
- Direct
- Footnotes
- F1, F2
ITOS
transaction
Common Stock
Options Exercise
- Transaction value
- $164,376
- Shares
- +38,227
- Change %
- Price
- $4.30
- Shares after
- 38,227
- Date
- 05 Jun 2025
- Ownership
- Direct
- Footnotes
- F1
ITOS
transaction
Common Stock
Sale
- Transaction value
- $388,004
- Shares
- -38,227
- Change %
- -100%
- Price
- $10.15
- Shares after
- 0
- Date
- 05 Jun 2025
- Ownership
- Direct
- Footnotes
- F1, F3
ITOS
transaction
Common Stock
Options Exercise
- Transaction value
- $164,380
- Shares
- +38,228
- Change %
- Price
- $4.30
- Shares after
- 38,228
- Date
- 06 Jun 2025
- Ownership
- Direct
- Footnotes
- F1
ITOS
transaction
Common Stock
Sale
- Transaction value
- $391,455
- Shares
- -38,228
- Change %
- -100%
- Price
- $10.24
- Shares after
- 0
- Date
- 06 Jun 2025
- Ownership
- Direct
- Footnotes
- F1, F4
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
ITOS
transaction
Derivative
Stock Option (Right to Buy)
Options Exercise
- Transaction value
- $0
- Shares
- -38,227
- Change %
- -33%
- Price
- $0.000000
- Shares after
- 76,455
- Date
- 04 Jun 2025
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 38,227
- Exercise price
- $4.30
- Footnotes
- F1
ITOS
transaction
Derivative
Stock Option (Right to Buy)
Options Exercise
- Transaction value
- $0
- Shares
- -38,227
- Change %
- -50%
- Price
- $0.000000
- Shares after
- 38,228
- Date
- 05 Jun 2025
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 38,227
- Exercise price
- $4.30
- Footnotes
- F1
ITOS
transaction
Derivative
Stock Option (Right to Buy)
Options Exercise
- Transaction value
- $0
- Shares
- -38,228
- Change %
- -100%
- Price
- $0.000000
- Shares after
- 0
- Date
- 06 Jun 2025
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 38,228
- Exercise price
- $4.30
- Footnotes
- F1
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Rule 10b5-1 trading plan
These transactions were reported as open-market trades under a Rule 10b5-1 plan. The plan lets an insider set trading instructions in advance, which can reduce the risk of trading while in possession of material nonpublic information.
Original filing language: transaction made pursuant to a contract, instruction, or written plan intended to satisfy Rule 10b5-1(c).
Explanation of responses 4 footnotes
Footnote F1
The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 5, 2025
Footnote F2
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $10.01 to $10.16, inclusive. The reporting person undertakes to provide to iTeos Therapeutics, Inc., any security holder of iTeos Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
Footnote F3
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $10.09 to $10.22, inclusive. The reporting person undertakes to provide to iTeos Therapeutics, Inc., any security holder of iTeos Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
Footnote F4
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $10.19 to $10.29, inclusive. The reporting person undertakes to provide to iTeos Therapeutics, Inc., any security holder of iTeos Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.